GenKOre

GenKOre is a South Korean biotechnology company specializing in the development of gene editing therapies for the treatment of genetic diseases. The company is built upon its proprietary TaRGET (Tiny nuclease and augment RNA-based Genome Editing Technology) platform, which utilizes hypercompact CRISPR-Cas systems. This technology is designed to overcome the delivery limitations of traditional large-sized nucleases by enabling efficient packaging and delivery via adeno-associated virus (AAV) vectors. By combining high precision and delivery efficiency, the platform facilitates advanced genetic analysis, gene editing research, and the development of therapeutic solutions for human and animal health.

This technology is significant for addressing unmet medical needs in various genetic disorders, including neurological conditions like Huntington’s disease and ALS. GenKOre collaborates with global pharmaceutical companies and research institutions through joint research and technology transfer agreements to translate its platform into clinical applications. The company’s innovative R&D efforts, including the development of hypercompact base editing systems, have received recognition as national strategic technologies in South Korea, underscoring its role in advancing next-generation gene therapy. Through its specialized research centers, GenKOre continues to expand its therapeutic pipeline and strategic partnerships to bring precise, effective genetic medicines to market.